NASDAQ:INGN • US45780L1044
The current stock price of INGN is 6.06 USD. Today INGN is down by -0.66%. In the past month the price increased by 4.66%. In the past year, price decreased by -18.66%.
ChartMill assigns a technical rating of 1 / 10 to INGN. When comparing the yearly performance of all stocks, INGN is a bad performer in the overall market: 80.87% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to INGN. While INGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
On February 24, 2026 INGN reported an EPS of -0.26 and a revenue of 81.72M. The company beat EPS expectations (28.7% surprise) and missed revenue expectations (-5.8% surprise).
8 analysts have analysed INGN and the average price target is 13.26 USD. This implies a price increase of 118.81% is expected in the next year compared to the current price of 6.06.
For the next year, analysts expect an EPS growth of -8.65% and a revenue growth 4.79% for INGN
Over the last trailing twelve months INGN reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 48.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.62% | ||
| ROE | -11.83% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.81 | 187.913B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.2 | 170.203B | ||
| SYK | STRYKER CORP | 22.27 | 129.047B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.77 | 101.721B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.52 | 49.099B | ||
| IDXX | IDEXX LABORATORIES INC | 38.71 | 45.48B | ||
| BDX | BECTON DICKINSON AND CO | 11.69 | 45.453B | ||
| RMD | RESMED INC | 18.8 | 33.857B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.69 | 32.053B | ||
| DXCM | DEXCOM INC | 25.27 | 25.116B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.99 | 18.115B | ||
| HOLX | HOLOGIC INC | 15.3 | 16.79B | ||
| PODD | INSULET CORP | 34 | 16.619B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California. The company went IPO on 2014-02-14. The company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. The company offers Simeox, which is an airway clearance device.
IPO: 2014-02-14
INOGEN INC
859 Ward Drive
Goleta CALIFORNIA 93117 US
CEO: Nabil Shabshab
Employees: 766
Phone: 18055620500
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California. The company went IPO on 2014-02-14. The company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. The company offers Simeox, which is an airway clearance device.
The current stock price of INGN is 6.06 USD. The price decreased by -0.66% in the last trading session.
INGN does not pay a dividend.
INGN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
INOGEN INC (INGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
INOGEN INC (INGN) currently has 766 employees.
INOGEN INC (INGN) will report earnings on 2026-05-05, after the market close.